

Sang Joon Shin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/167701/sang-joon-shin-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

1,996
citations

24
h-index

39
g-index

135
ext. papers

2,423
ext. citations

4.5
avg, IF

4.48
L-index

#	Paper	IF	Citations
130	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
129	A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 95-95	2.2	0
128	Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.. <i>Anticancer Research</i> , 2022 , 42, 589-598	2.3	1
127	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2022 , 14, 2659	6.6	2
126	470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59) 2021 , 9, A499-A499		1
125	Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival. <i>Frontiers in Oncology</i> , 2021 , 11, 747250	5.3	1
124	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1029-1039 ^{2,2} 1039 ^{4,3}		
123	Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2021 , 53, 1174-1183	5.2	1
122	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021 , 39, 1335-1347	4.3	0
121	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021 , 594, 418-423	50.4	20
120	Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2814-2820 ^{2,6} 2820		1
119	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 491-514	2.5	0
118	Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16578- e16578 ^{2,2} e16578		
117	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021 , 11, 659754	5.3	1
116	Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. <i>World Allergy Organization Journal</i> , 2021 , 14, 100553 ^{5,2} 100553		2
115	Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF Mutation-Positive Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2021 , 10, 39-45	2.3	2
114	Autonomy is not but competence and relatedness are associated with physical activity among colorectal cancer survivors. <i>Supportive Care in Cancer</i> , 2021 , 29, 1653-1661	3.9	1

113	Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021 , 47, 128226	2.9	3
112	Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View. <i>Yonsei Medical Journal</i> , 2021 , 62, 569-576	3	0
111	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e140-e150	3.8	3
110	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020 , 135, 31-38	7.5	5
109	Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2774-2783	3.1	6
108	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 61-70	12.9	14
107	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5034-5034	3.2	3
106	Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS591-TPS591	2.2	1
105	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020 , 52, 730-738	5.2	4
104	Clinical features and KRAS mutation in colorectal cancer with bone metastasis. <i>Scientific Reports</i> , 2020 , 10, 21180	4.9	6
103	Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1071-1079	4.5	4
102	Objectively measured physical activity during chemotherapy in colon cancer patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 2597-2604	3.9	1
101	Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. <i>Trials</i> , 2020 , 21, 320	2.8	4
100	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019 , 9, 835	5.3	21
99	Treatment Outcomes of Re-irradiation in Locoregionally Recurrent Rectal Cancer and Clinical Significance of Proper Patient Selection. <i>Frontiers in Oncology</i> , 2019 , 9, 529	5.3	7
98	VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. <i>Science Immunology</i> , 2019 , 4,	2.8	77
97	Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3000-3000	2.2	13
96	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4569-4569	2.2	18

95	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4570-4570	2.2	12
94	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 546-546	2.2	35
93	Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer. <i>Asian Oncology Nursing</i> , 2019 , 19, 204	0.4	
92	Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. <i>Journal of Cancer Prevention</i> , 2019 , 24, 48-53	3	
91	IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors. <i>Cancer Immunology Research</i> , 2018 , 6, 685-695	12.5	27
90	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. <i>Cancer Immunology Research</i> , 2018 , 6, 255-266	12.5	91
89	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e513-e518	3.8	14
88	Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1119-1128	4.9	3
87	Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. <i>Cancer Research</i> , 2018 , 78, 5315-5326	10.1	26
86	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4500-4500	2.2	65
85	Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. <i>Cancer Research and Treatment</i> , 2018 , 50, 1238-1251	5.2	7
84	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018 , 50, 1378-1387	5.2	8
83	The role of endoscopic evaluation for radiation proctitis in patients receiving intermediate-dose postoperative radiotherapy for rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018 , 48, 988-994	2.8	1
82	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018 , 59, 588-594	3	18
81	Sunrise in melanoma management: Time to focus on melanoma burden in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 423-427	1.9	16
80	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 773-781	4.3	4
79	IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. <i>Nature Communications</i> , 2017 , 8, 15776	17.4	86
78	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. <i>BMC Cancer</i> , 2017 , 17, 615	4.8	8

77	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , 2017 , 14, 2385-2392	2.6	5
76	Quality of life among Korean gastrointestinal cancer survivors. <i>European Journal of Oncology Nursing</i> , 2017 , 30, 15-21	2.8	8
75	Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancer. <i>Journal of Radiation Research</i> , 2017 , 58, 559-566	2.4	3
74	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 227-235	3.1	28
73	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. <i>American Journal of Cancer Research</i> , 2017 , 7, 134-138	4.4	6
72	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017 , 49, 44-53	5.2	19
71	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2051-9	4.9	9
70	Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 928-35	3.1	22
69	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. <i>Radiotherapy and Oncology</i> , 2016 , 118, 369-74	5.3	24
68	p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 208-15	5.2	9
67	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. <i>Cancer Research and Treatment</i> , 2016 , 48, 1210-1221	5.2	9
66	Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. <i>PLoS ONE</i> , 2016 , 11, e0161475	3.7	19
65	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. <i>British Journal of Cancer</i> , 2016 , 115, 25-33	8.7	87
64	Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 911-918	2.8	6
63	Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1520-6	3.1	11
62	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 1015-22	4	21
61	PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015 , 136, 2273-83	7.5	9
60	Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients. <i>Oncology</i> , 2015 , 88, 195-200	3.6	1

59	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 2015 , 47, 9-17	5.2	7
58	Novel methods for clinical risk stratification in patients with colorectal liver metastases. <i>Cancer Research and Treatment</i> , 2015 , 47, 242-50	5.2	5
57	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015 , 47, 781-9	5.2	7
56	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014 , 32, 561-8	4.3	2
55	Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 399-409	4.9	4
54	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014 , 12, 232	3.4	27
53	Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. <i>Journal of Surgical Oncology</i> , 2014 , 110, 214-21	2.8	28
52	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3608-3608	2.2	
51	Assessment of efficiency and safety of the comprehensive Chemotherapy Assistance Program for ordering oncology medications. <i>International Journal of Medical Informatics</i> , 2013 , 82, 504-13	5.3	11
50	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013 , 21, 1751-9	3.9	27
49	Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3407-13	3.1	50
48	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013 , 31, 1-13	4.3	10
47	Quantitation and pharmacokinetics of 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) in rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Separation Science</i> , 2013 , 36, 239-45	3.4	3
46	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013 , 107, 613-8	2.8	17
45	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 853-60	3.5	5
44	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 265-72	1.9	8
43	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 492-492	2.2	1
42	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 511-511	2.2	1

41	Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 91-7	3.5	
40	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 672-80	4.3	14
39	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012 , 12, 471	4.8	1
38	VIPoma that arose from the rectum in a 65-year-old male patient. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 1385-6	3	2
37	Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. <i>Surgical Oncology</i> , 2012 , 21, e125-30	2.5	5
36	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 1501-10	4.3	17
35	Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. <i>European Radiology</i> , 2012 , 22, 1693-700	8	78
34	Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. <i>American Journal of Roentgenology</i> , 2012 , 199, 809-15	5.4	60
33	Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. <i>Cancer Research and Treatment</i> , 2012 , 44, 43-9	5.2	13
32	Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3606-3606	2.2	
31	Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14084-e14084	2.2	4
30	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14072-e14072	2.2	
29	Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 669-76	4	26
28	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2011 , 22, 801-10	2.4	13
27	Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2011 , 29, 1073-80	4.3	6
26	Brain metastases from colorectal carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 49-55	4.8	65
25	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 991-9	3.5	4
24	Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. <i>Radiation Oncology</i> , 2011 , 6, 99	4.2	30

23	Comparison of diffusion-weighted MRI and MR volumetry in the evaluation of early treatment outcomes after preoperative chemoradiotherapy for locally advanced rectal cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2011 , 34, 570-6	5.6	54
22	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011 , 117, 2050-7	6.4	38
21	DNA methylation predicts recurrence from resected stage III proximal colon cancer. <i>Cancer</i> , 2011 , 117, 1847-54	6.4	126
20	Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. <i>Oncology</i> , 2011 , 80, 107-17	3.6	10
19	Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. <i>Oncology</i> , 2011 , 81, 175-83	3.6	16
18	A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy. <i>Cancer Research and Treatment</i> , 2010 , 42, 235-8	5.2	19
17	Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m ² bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 29-35	2.8	2
16	Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. <i>Lung Cancer</i> , 2010 , 70, 77-81	5.9	14
15	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010 , 288, 124-32	9.9	30
14	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010 , 95, 303-7	5.3	21
13	A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 56-60	2.7	2
12	Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 387-94	4.9	31
11	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010 , 28, 650-8	4.3	15
10	The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. <i>Radiation Oncology</i> , 2010 , 5, 75	4.2	21
9	Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. <i>Yonsei Medical Journal</i> , 2009 , 50, 296-9	3	2
8	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 919-27	3.5	5
7	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 27-32	3.5	20
6	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009 , 34, 787-96	1	1

5	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008 , 270, 269-76	9.9	5
4	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 75-81	3.5	9
3	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 157-65	3.5	11
2	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 309-13	3.5	11
1	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007 , 46, 547-9	3.2	0